Skip to main content
. 2020 Aug 15;12(8):2295. doi: 10.3390/cancers12082295

Table 2.

Expression levels of ZKSCAN3 in radical prostatectomy specimens.

n Levels of ZKSCAN3 Expression p IHC Score
(mean ± SD)
p (t-Test)
0 1+ 2+ 3+ 1+/2+/3+ 0 vs. 1+/2+/3+ 0/1+ vs. 2+/3+ 0/1+/2+ vs. 3+
Benign 150 99 (66%) 44 (29%) 6 (4%) 1 (1%) 51 (34%) <0.001 *1 <0.001 *1 0.301 *1 1.65 ± 1.41 <0.001 *1
HGPIN 146 54 (37%) 68 (47%) 21 (14%) 3 (2%) 92 (63%) <0.001 *2 <0.001 *2 <0.001 *2 2.58 ± 1.66 <0.001 *2
Carcinoma 300 21 (7%) 99 (33%) 95 (32%) 85 (28%) 279 (93%) <0.001 *3 <0.001 *3 <0.001 *3 5.20 ± 2.33 <0.001 *3
Age (mean ± SD, year) 300 58.0 ± 4.8 60.2 ± 6.4 60.2 ± 6.1 60.8 ± 6.1 60.4 ± 6.2 0.079 0.363 0.275 NA
PSA (mean ± SD, ng/mL) 300 5.72 ± 3.27 6.02 ± 3.07 7.21 ± 4.88 6.44 ± 3.87 6.31 ± 3.91 0.441 0.243 0.623 NA
Gleason score (GS)/Grade Group (GG)
GS ≤ 6/GG 1 107 11 (10%) 32 (30%) 44 (41%) 20 (19%) 96 (90%) 0.097 *4 0.961 *4 0.006 *4 4.91 ± 2.15 0.099 *4
GS 3 + 4 = 7/GG 2 127 9 (7%) 52 (41%) 36 (28%) 30 (24%) 118 (93%) 0.048 *5 0.003 *5 <0.001 *5 4.85 ± 2.34 <0.001 *5
GS 4 + 3 = 7/GG 3 46 1 (2%) 11 (24%) 9 (20%) 25 (54%) 45 (98%) 0.204 *6 0.059 *6 0.026 *6 6.26 ± 2.28 0.010 *6
GS ≥ 8/GG 4–5 20 0 (0%) 4 (20%) 6 (30%) 10 (50%) 20 (100%) 6.50 ± 2.09
Pathologic stage (pT)
2 235 15 (6%) 88 (37%) 79 (34%) 53 (23%) 220 (94%) 0.426 *7 0.010 *7 <0.001 *7 4.95 ± 2.19 <0.001 *7
3a 47 6 (13%) 9 (19%) 13 (28%) 19 (40%) 41 (87%) 0.230 *8 0.010 *8 <0.001 *8 5.51 ± 2.58 <0.001 *8
3b 18 0 (0%) 2 (11%) 3 (17%) 13 (72%) 18 (100%) 7.61 ± 1.90
Lymph node metastasis (pN) 0.326 0.075 0.021 0.002
0 154 15 (10%) 48 (31%) 45 (29%) 46 (30%) 139 (90%) 5.05 ± 2.46
1 9 0 (0%) 1 (11%) 2 (22%) 6 (67%) 9 (100%) 7.67 ± 1.94
History of vasectomy 0.293 0.044 0.217 0.018
No 286 21 (7%) 97 (34%) 89 (31%) 79 (28%) 265 (93%) 5.13 ± 2.33
Yes 14 0 (0%) 2 (14%) 6 (43%) 6 (43%) 14 (100%) 6.64 ± 1.79

*1 Benign vs. HGPIN. *2 HGPIN vs. Carcinoma. *3 Benign vs. Carcinoma. *4 GG1 vs. GG2-5. *5 GG1-2 vs. GG3-5. *6 GG1-3 vs. GG4-5. *7 pT2 vs. pT3. *8 pT2/pT3a vs. pT3b.